• G-15: A Selective G Protein-Coupled Estrogen Receptor Antago

  2026-04-27

  G-15, a highly selective G protein-coupled estrogen receptor antagonist, enables precise dissection of GPR30-mediated estrogen signaling in both in vitro and in vivo models. Its robust workflow compatibility and validated specificity make it indispensable for advanced estrogen signaling research, particularly in neurobiology and pain circuitry studies.

• (-)-JQ1: The Gold-Standard BET Bromodomain Inhibitor Control

  2026-04-27

  (-)-JQ1, the inactive JQ1 stereoisomer, is the definitive negative control for BET bromodomain studies in epigenetics and cancer biology research. Leveraging precise chemical inertness, it enables reproducible workflows and rigorous on-target validation, elevating experimental reliability in BRD4-dependent cell models.

• LGK-974: Strategic PORCN Inhibition for Translational Impact

  2026-04-26

  This thought-leadership article explores how LGK-974, a potent and highly specific PORCN inhibitor from APExBIO, is redefining the translational landscape of Wnt-driven cancer therapy. By bridging mechanistic depth with actionable guidance, the article situates LGK-974 at the frontier of precision oncology, emphasizing its utility in dissecting Wnt pathway biology and advancing research in challenging models such as RNF43-mutant pancreatic cancer. Drawing on recent mechanistic insights, validated experimental protocols, and the evolutionary context of Wnt signaling, the piece offers strategic direction for translational researchers while situating its guidance above traditional product pages.

• Zolmitriptan as a 5-HT1B Agonist: Assay Design, Lysosomal Cr

  2026-04-25

  Explore Zolmitriptan's role as a 5-HT1B receptor agonist in advanced migraine research, with a unique focus on integrating serotonin receptor pharmacology and lysosomal biology. Discover novel insights for translational assay design and research reproducibility.

• Refining In Vitro Cancer Drug Response: Distinguishing Growt

  2026-04-24

  Schwartz's dissertation introduces a rigorous framework for evaluating anti-cancer drug effects in vitro by differentiating proliferative arrest from cell death, challenging the conventional use of relative viability as a sole metric. This approach enhances the accuracy of drug response analysis and holds practical value for researchers designing kinase inhibitor studies.

• FITC-Concanavalin A (ConA) Conjugate: Technical Lab Guidance

  2026-04-24

  FITC-Concanavalin A (ConA) Conjugate provides a robust solution for direct, fluorescence-based detection of α-D-glucose and α-D-mannose residues on cell surfaces, supporting workflows in immunofluorescence, flow cytometry, and glycobiology research. It is designed for carbohydrate-specific applications and should not be used outside its defined stability window or for non-carbohydrate-binding assays.

• hiPSC-Derived Intestinal Organoids Advance CYP2C19 Substrate

  2026-04-23

  This study introduces a streamlined protocol for generating intestinal organoids from human pluripotent stem cells, enabling high-fidelity modeling of human intestinal drug metabolism. The approach provides a reproducible, scalable platform for pharmacokinetic studies with improved physiological relevance compared to traditional models.

• Applied Insights: EdU Imaging Kits (Cy3) for S-Phase DNA Ana

  2026-04-23

  EdU Imaging Kits (Cy3) deliver denaturation-free, high-sensitivity DNA synthesis detection for cell proliferation and genotoxicity workflows. This article breaks down experimental best practices, protocol optimization, and troubleshooting strategies, translating recent developmental biology findings into actionable guidance for advanced users.

• Q-VD(OMe)-OPh: Precision Caspase Inhibition in Apoptosis Ass

  2026-04-22

  Q-VD(OMe)-OPh delivers highly selective, low-toxicity pan-caspase inhibition, enabling reproducible apoptosis research across oncology and neuroprotection models. This guide details protocol refinements, troubleshooting, and strategic benefits that set Q-VD(OMe)-OPh apart from traditional caspase inhibitors.

• Epigenetic Mcl-1 Targeting Synergizes with BCL-XL Inhibition

  2026-04-22

  This study demonstrates that epigenetic suppression of Mcl-1, combined with BCL-XL/BCL-2 inhibition, produces a synthetic lethal effect in glioblastoma models. The findings highlight a promising strategy to overcome apoptosis resistance in aggressive brain tumors and offer mechanistic insights for future therapeutic development.

• 20-HETE–TRPV1 Axis in Chronic Dermatitis: Sensory Pathways U

  2026-04-21

  This study uncovers how the lipid metabolite 20-HETE activates TRPV1 channels on MrgprA3+ sensory neurons, driving allokinesis and chronic itch in dermatitis. The findings clarify sensory neuron cross-talk in itch-pain modulation and offer new intervention points for dermatological research.

• FITC Goat Anti-Rabbit IgG (H+L) Antibody: Sensitivity in Imm

  2026-04-21

  The FITC Goat Anti-Rabbit IgG (H+L) Antibody by APExBIO delivers robust, reproducible signal amplification for biomarker detection in immunofluorescence and flow cytometry. This guide details optimized protocols, troubleshooting, and cutting-edge applications, bridging novel bench research with practical assay choices.

• O-GlcNAcylation's Role in Wnt-Stimulated Bone Formation and

  2026-04-20

  This study uncovers how O-GlcNAcylation acts as an essential mediator of Wnt3a-induced bone formation by remodeling aerobic glycolysis in osteoblasts. The findings provide mechanistic insight into glucose metabolism during osteogenesis and suggest new metabolic targets for bone anabolic therapies.

• Epigenetic Mcl-1 Targeting Synergizes with BCL-XL Inhibition

  2026-04-20

  This study identifies a super-enhancer at the Mcl-1 locus in glioblastoma and demonstrates that combining epigenetic suppression of Mcl-1 with BCL-XL/BCL-2 inhibition triggers robust apoptosis. The work reveals a promising synthetic lethal strategy for overcoming resistance in aggressive brain tumors, with important implications for targeted cancer therapy.

• A-769662: AMPK Activator Workflows for Energy Metabolism Res

  2026-04-19

  A-769662 offers precision AMPK activation, uniquely enabling studies that dissect energy metabolism, fatty acid synthesis inhibition, and proteasome regulation. This guide delivers actionable protocols, troubleshooting strategies, and experimental insights for leveraging A-769662 in metabolic and cell cycle research.

16247 records 1/1084 page Next 12345 下5页 Last page